In the subsequent trial, called the Normal Risk of Ovarian Cancer screening study (NROSS), postmenopausal women were tested using the ROCA algorithm and then selected for consecutive annual CA125 tests (low risk), repeat CA125 test in 3 months (intermediate risk), or transvaginal ultrasound and gynecologic oncologist consultation (high risk). The gene discussed is MUC16; the disease is ovarian cancer.